Exagen Company Leadership
| XGN Stock | USD 4.07 0.01 0.25% |
Exagen employs about 174 people. The company is managed by 11 executives with a total tenure of roughly 406 years, averaging almost 36.0 years of service per executive, having 15.82 employees per reported executive. Analysis of Exagen's management performance can provide insight into the firm performance.
Exagen |
Exagen Management Team Effectiveness
The company has Return on Asset of (0.1741) % which means that on every $100 spent on assets, it lost $0.1741. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.6997) %, meaning that it generated no profit with money invested by stockholders. Exagen's management efficiency ratios could be used to measure how well Exagen manages its routine affairs as well as how well it operates its assets and liabilities.Exagen Workforce Comparison
Exagen Inc is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 8,764. Exagen claims roughly 174 in number of employees contributing just under 2% to equities under Health Care industry.
The company has Net Profit Margin of (0.31) %, which means that it does not effectively control expenditures or properly executes on its pricing strategies. This is way below average. In the same way, it shows Net Operating Margin of (0.17) %, which entails that for every $100 of revenue, it lost $0.17. Exagen Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Exagen insiders, such as employees or executives, is commonly permitted as long as it does not rely on Exagen's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Exagen insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Rocca Fortunato R. 3 days ago Disposition of 4322 shares by Rocca Fortunato R. of Exagen at 7.12 subject to Rule 16b-3 | ||
Nmsic Co-investment Fund, L.p. over two months ago Disposition of 200000 shares by Nmsic Co-investment Fund, L.p. of Exagen at 3.3002 subject to Rule 16b-3 | ||
Birk Brian over three months ago Acquisition by Birk Brian of 9000 shares of Exagen subject to Rule 16b-3 | ||
Hunt Holdings Limited Partnership over three months ago Disposition of 30000 shares by Hunt Holdings Limited Partnership of Exagen at 16.133 subject to Rule 16b-3 | ||
Black Jeffrey G. over three months ago Acquisition by Black Jeffrey G. of 225000 shares of Exagen subject to Rule 16b-3 | ||
Stokes Frank over six months ago Insider Trading | ||
Adawi Kamal over six months ago Disposition of 9297 shares by Adawi Kamal of Exagen at 1.9089 subject to Rule 16b-3 | ||
Adawi Kamal over six months ago Disposition of 3487 shares by Adawi Kamal of Exagen at 1.9099 subject to Rule 16b-3 |
Exagen Notable Stakeholders
An Exagen stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Exagen often face trade-offs trying to please all of them. Exagen's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Exagen's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| John Aballi | President, CEO | Profile | |
| Tina Nova | Executive Directors | Profile | |
| Jeffrey Black | Chief Officer | Profile | |
| Debra Zack | Chief Officer | Profile | |
| John Wegener | Senior Marketing | Profile | |
| Ryan Douglas | Investors Officer | Profile | |
| Mark Hazeltine | Chief Officer | Profile | |
| MingChou Lee | Chief Officer | Profile | |
| Michael MD | Chief Officer | Profile | |
| MD FACR | Chief Board | Profile | |
| MBA MS | Corporate Secretary | Profile |
About Exagen Management Performance
The success or failure of an entity such as Exagen Inc often depends on how effective the management is. Exagen management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Exagen management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Exagen management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California. Exagen operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 219 people.
Exagen Workforce Analysis
Traditionally, organizations such as Exagen use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Exagen within its industry.Exagen Manpower Efficiency
Return on Exagen Manpower
| Revenue Per Employee | 302K | |
| Revenue Per Executive | 4.8M | |
| Net Loss Per Employee | 136.1K | |
| Net Loss Per Executive | 2.2M | |
| Working Capital Per Employee | 206.5K | |
| Working Capital Per Executive | 3.3M |
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Exagen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Healthcare space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exagen. If investors know Exagen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exagen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Exagen Inc is measured differently than its book value, which is the value of Exagen that is recorded on the company's balance sheet. Investors also form their own opinion of Exagen's value that differs from its market value or its book value, called intrinsic value, which is Exagen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exagen's market value can be influenced by many factors that don't directly affect Exagen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Exagen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Exagen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exagen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.